Risk factors for rifampin-monoresistant tuberculosis: A case-control study.

@article{Sandman1999RiskFF,
  title={Risk factors for rifampin-monoresistant tuberculosis: A case-control study.},
  author={Laurie Sandman and Neil W Schluger and Amy Davidow and Sigrid Bonk},
  journal={American journal of respiratory and critical care medicine},
  year={1999},
  volume={159 2},
  pages={468-72}
}
Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or in combination with other antituberculous medications. We conducted a retrospective case-control study to identify risk factors for RMR-TB. Complete records for 21 of a total of 26 RMR patients from 1990 to 1997 were available for review, and were compared with those of 48 patients with drug-susceptible TB… CONTINUE READING